Margaret is a Managing Director with Deloitte Consulting where she brings her biomedical program, policy, and patient engagement experience to strategy projects in the Federal Health and nonprofit area. She recently led high-impact COVID-19 projects across the federal health space focused on public-private partnerships, community response, risk mitigation, and overall impacts of the pandemic on our nonprofit sector. Margaret was a founding board member and past president of the Alliance for a Stronger FDA, as well as the NIH National Center for Advancing Translational Sciences Advisory Council and the Cures Acceleration Network Review Board. She served previously on the boards of the National Health Council, United for Medical Research, the Food and Drug Administration's Science Board, Science Looking Forward Committee, and the National Academy of Medicine’s Forum on Drug Discovery, Development, and Translation. She currently serves on the Boards of Act for NIH, Allen Institute, Alliance for Regenerative Medicine Foundation, FasterCures, Friends of Cancer Research, and Melanoma Medicine Foundation.